逐瘀消瘤方佐治结直肠癌瘀毒内结型患者的临床研究  

A clinical study on treating colorectal cancer of the Yudu Neijie type with the Zhuyu Xiaoliu prescription

作　　者：易良杰[1] 涂建龙 李升伟[1] 

机构地区：[1]惠州市中医医院,广东惠州516001

出　　处：《中医临床研究》2018年第28期5-7,共3页Clinical Journal Of Chinese Medicine

摘　　要：目的:观察逐瘀消瘤方佐治结直肠癌瘀毒内结型患者的临床疗效。方法:将60名患者随机分为治疗组(30例)和对照组(30例),对照组给予大肠癌一线常规化疗方案治疗,治疗组在奥沙利铂联合卡培他滨化疗的基础上加服逐瘀消瘤方,共治疗2个周期,每3周为一个周期。观察两组患者治疗前后患者实体瘤疗效评价、CEA和CA199变化及生活质量评分变化。结果:治疗后两组患者实体瘤疗效评价有统计学差异(P <0.05),且治疗组疗效优于对照组;两组CEA和CA199治疗后均较治疗前显著下降(P <0.01),且治疗组较对照组下降明显(P <0.05);KPS评分方面,治疗组治疗后评分改善明显(P <0.01),对照组治疗后改善不明显(P> 0.05),两组治疗后组间比较有统计学差异(P <0.05),治疗组优于对照组。结论:逐瘀消瘤方联合常规化疗能提高结直肠癌瘀毒内结型患者的治疗效果,提高患者生活质量,具有增效减毒的作用,值得临床推广。Objective:To observe the clinical efficacy of the Zhuyu Xiaoliu prescription(逐瘀消瘤方)on colorectal cancer of the Yudu Neijie type(瘀毒内结型).Methods:60 patients were randomly divided into the treatment group(30 cases)and control group(30 cases).The control group was treated by conventional chemotherapy.The treatment group was treated with the Zhuyu Xiaoliu prescription more.The therapeutic evaluation of solid tumor,CEA,CA199 and life quality score before and after the treatment in two groups were observed.Results:There were significant differences between two groups in solid tumor after treatment(P<0.05),while in treatment group was better than the control group.The CEA and CA199 in two groups were decreased significantly after treatment(P<0.01),and those in the treatment group were declined obviously(P<0.05).The KPS was significantly improved in the treatment group after treatment(P<0.01)and the improvement in the control group was not obvious(P>0.05).There were significant differences between two groups after treatment(P<0.05),and the treatment group was better than the control group.Conclusion:The Zhuyu Xiaoliu prescription plus conventional chemotherapy can increase the efficacy and life quality,with efficacy enhancing and toxicity reducing,and it worth of further study and promotion.

关 键 词：逐瘀消瘤方 结直肠癌 瘀毒内结 佐治 

分 类 号：R735.37[医药卫生—肿瘤]